CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 80 enrolled
Drug / intervention
preoperative intravitreal injections of ranibizumab or conberceptprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05414149
NCT05414149N/ACompleted
CompareCT.gov

Efficacy and Safety Comparison of Ranibizumab and Conbercept Pretreatment Before Vitrectomy in Proliferative Diabetic Retinopathy

Peking University People's Hospital·interventional·Posted Jun 10, 2022·Updated Jun 10, 2022

In Brief

A clinical study evaluating preoperative intravitreal injections of ranibizumab or conbercept for Proliferative Diabetic Retinopathy. Completed, enrolled 80 participants across 1 site.

Detailed Summary

Proliferative diabetic retinopathy (PDR) is the most common causes of irreversible blindness in diabetic retinopathy (DR).Although pars plana vitrectomy (PPV) is the cornerstone for treatment of advanced PDR, related postoperative complications such as recurrent VH, NVG, and postoperative fibrovascular proliferation progression may still cause serious visual impairment. Preoperative intravitreal injections of anti-VEGF drugs may represent a new strategy for making vitrectomy safer and more effective for severe PDR.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProliferative Diabetic Retinopathy
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedJun 10, 2022
Enrollment StartSep 1, 2021
Primary CompletionMay 31, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 4.1 years ago

Interventions

preoperative intravitreal injections of ranibizumab or conberceptprocedure

IVR group means patients received intravitreal ranibizumab injections (IVR) (0.5mg/0.05ml) before vitreous surgery. IVC group means patients that received intravitreal conbercept injection (IVC) (0.5mg/0.05ml) before vitreous surgery.